實踐 WHO 願景：臺灣終結C型肝炎為公共衛生威脅之路
石崇良部長
臺灣衛生福利部
C 型肝炎長期以來被視為全球重大的公共衛生挑戰，全球約有5,800萬人罹患慢性C型肝 炎。儘管目前尚無C型肝炎疫苗，但隨著抗病毒藥物(direct-acting antiviral, DAA)的問世， C肝已可在8-12週療程內有效治癒，也為各國實現消除目標奠定堅實基礎。因此，世界衛 生組織(World Health Organization, WHO)於 2015 年發布《病毒性肝炎格拉斯哥宣言》，訂 下於2030年消除病毒性肝炎為公共衛生威脅的願景。
依循 WHO《消除病毒性肝炎國家驗證指引及消除路徑(Path to Elimination, PTE)》架構， 臺灣已在C肝防治上達成 WHO PTE架構下的金級(Gold Tier)目標。此一成果是基於我國 政府的政策決心，並將肝炎預防、篩檢、診斷與治療，系統性整合於健康照護體系中的實現。
透過成人預防保健服務中納入 B、C 型肝炎篩檢，以及全民健康保險制度的DAA藥物的給 付，臺灣提供普及的C肝篩檢與治療服務，從而有效降低民眾在經濟與制度層面的就醫障 礙。結果顯示，截至2025年6月，我國估計有90.2%的C肝感染者已被診斷，其中約 92.6%已接受DAA治療，相關指標優於WHO所訂定之PTE金級標準。
在C肝消除工作中，預防與病人安全是不可或缺的關鍵要素。臺灣輸血血品及醫療注射安 全率皆達100%。同時，我們也透過完善的減害政策，確保注射藥物族群能取得安全針具並 達每人每年平均超過150支。這些措施對於降低新感染的風險，以及維持長期消除成果極 具關鍵。
秉持 WHO 及聯合國永續發展目標「不遺漏任何一人」的原則，臺灣也關心感染風險較 高、照護可近性相對不足的族群。包括 HIV 感染者、末期腎臟病患者、接受鴉片類替代治 療者及監獄收容人。相關族群皆大部分已達到高篩檢涵蓋率以及治療率。這些成果展現臺灣 健康體系的公平性，以及對應WHO的核心原則。
在我國長期推動肝炎防治政策下，過去二十年臺灣肝癌的發生率與死亡率均呈現顯著下降趨 勢。我國於2025年公布《臺灣消除C型肝炎報告》，報告中各項成果可歸功於中央與地方 政府、公共衛生機關、臨床醫療體系以及公民社會組織之間的密切跨部門合作。臺灣消除C 肝的成功，也根基於堅定的政府政策決心，輔以健全的監測照護系統及資料公開透明作為支 撐。
在全球共同邁向 2030 年病毒性肝炎消除目標的進程中，「臺灣模式」展現當科學證據、 政治承諾與健康公平相互支持下，消除 C肝是可以實現的目標。我們已將《臺灣消除C型 肝炎報告》提交世界衛生組織西太平洋地區署(Western Pacific Regional Office, WPRO)， 以申請消除C肝之PTE金級認證，並期盼WHO肯定臺灣在消除C肝方面的成果與貢獻。 臺灣願持續與國際社會攜手合作，分享我國經驗，加速邁向無 C 型肝炎的全球目標。
Delivering on the WHO Vision: Taiwan’s Path Toward Ending Hepatitis C as a Public Health Threat
Dr. Chung-Liang Shih
Minister of Health and Welfare, Taiwan
For decades, hepatitis C has been recognized as a major global public health challenge, with an estimated 58 million people living with chronic hepatitis C infection worldwide. Although no vaccine currently exists, hepatitis C is now curable with highly effective direct-acting antiviral (DAA) therapies delivered through treatment courses of 8–12 weeks. Therefore, the World Health Organization (WHO) launched the Glasgow Declaration on Viral Hepatitis in 2015, setting ambitious goals to eliminate viral hepatitis as a public health threat by 2030.
In line with the WHO’s Guidance for Country Validation of Viral Hepatitis Elimination and Path to Elimination, Taiwan has reached the Gold Tier programmatic targets under the WHO Path to Elimination (PTE) framework for hepatitis C. This progress has been driven by the government’s political will and the systematic integration of hepatitis prevention, screening, diagnosis, and treatment into a universal health-care system.
Through Taiwan’s Adult Preventive Healthcare Services for hepatitis B and C, as well as the National Health Insurance program for DAA reimbursement, hepatitis C screening and treatment are widely available, thereby reducing financial and structural barriers to care. As of June 2025, an estimated 90.2% of individuals with chronic hepatitis C have been diagnosed, and 92.6% of those diagnosed have received DAA treatment, exceeding the WHO PTE Gold Tier benchmarks.
Prevention and patient safety remain indispensable components of hepatitis C elimination. Taiwan maintains 100% screening of donated blood and 100% safe medical injection practices. Comprehensive harm reduction programs are also provided to ensure wide access to sterile injecting equipment for people who inject drugs (PWID), with more than 150 syringes distributed per person. These measures are essential for reducing new infections and safeguarding elimination gains over time.
Consistent with the WHO and Sustainable Development Goals (SDGs) principle of Leave No One Behind, Taiwan has focused on populations facing higher risks and greater barriers to care. High screening coverage and treatment rates have been achieved among people living with HIV, patients with end-stage renal disease, individuals receiving opioid agonist therapy, and prisoners in correctional facilities. These outcomes reflect the equity of our healthcare systems and reflect the WHO’s core principle.
Over the past two decades, Taiwan has observed a substantial decline in liver cancer incidence and mortality, trends closely linked to long-standing hepatitis prevention and treatment policies. The achievements presented in the Taiwan Hepatitis C Elimination Report are the result of close cross-sectoral collaboration among central and local governments, public health authorities, clinical providers, and civil society organizations. Taiwan’s success is also rooted in the government’s political will, supported by robust surveillance systems and transparent data reporting.
As the global target toward the 2030 viral hepatitis elimination goals, the "Taiwan Model" offers clear evidence that elimination is achievable when science, political will, and equity converge. The Taiwan Hepatitis C Elimination Report has been submitted to the WHO Western Pacific Regional Office (WPRO) for validation under the PTE Gold Tier for hepatitis C elimination. We look forward to the recognition of Taiwan’s demonstrated leadership and contributions in advancing hepatitis C elimination. Taiwan remains committed to working with the international community and sharing our experience to help accelerate global progress toward a world free from hepatitis C.
